Zydus Lifesciences Ltd. NSE: ZYDUSLIFE | BSE: 532321

Strong Performer, Getting Expensive

Download real time

1035.80 -3.80 (-0.37%)

30.29% Gain from 52W Low

188.3K

NSE+BSE Volume

NSE 11 Sep, 2025 10:29 AM (IST)

Zydus Lifesciences Ltd. share price target

Zydus Lifesciences Ltd. has an average share price target of 1045.33. The consensus estimate represents an upside of 0.92% from the last price of 1035.80. View 13 reports from 6 analysts offering long-term price targets for Zydus Lifesciences Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	11 Sep 2025	Zydus Lifesciences	Consensus Share Price Target	1035.80	1006.63	-	-2.82	hold	pdf Detailed Estimates
	06 Feb 2025	Zydus Lifesciences	ICICI Securities Limited Target	1035.80	1000.00	1008.20 (2.74%)	Target met	Hold	pdf post cache		Broker Report Near-term challenges persist in US ICICI Securities Limited Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. pdf Copy Link Share on Share on Share on Share on Alert
	06 Feb 2025	Zydus Lifesciences	Prabhudas Lilladhar Target	1035.80	1050.00	1008.20 (2.74%)	1.37	Accumulate	pdf post cache		Broker Report ZYDUS LIFESCIENCES L Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	18 Nov 2024	Zydus Lifesciences	Sharekhan Target	1035.80	1078.00	944.70 (9.64%)	4.07	Buy	pdf post cache		Broker Report Sustained Growth Across All Segments Sharekhan Revenue amounted to Rs. 5,237 crore, reflecting a 20% y-o-y increase but a 16% q-o-q decline, primarily driven by reduced performance in the Indian consumer wellness segment, US formulations and API business. pdf Copy Link Share on Share on Share on Share on Alert
	12 Nov 2024	Zydus Lifesciences	Motilal Oswal Target	1035.80	1010.00	949.75 (9.06%)	Target met	Neutral	pdf post cache		Broker Report The US and international markets drive earnings Motilal Oswal Zydus LifeSciences (ZYDUSLIF) delivered better-than-expected operational performance for the quarter. While its revenue grew at a lower rate of 19% YoY (vs. est. of 25%). pdf Copy Link Share on Share on Share on Share on Alert
	03 Oct 2024	Zydus Lifesciences	Sharekhan Target	1035.80	1268.00	1069.05 (-3.11%)	22.42	Buy	pdf post cache		Broker Report R&D advancements to drive growth Sharekhan Zydus Lifesciences Ltd has partnered with the Central Drug Research Institute (CDRI) to develop an oral treatment for osteoporosis related to chronic kidney disease (CKD) and postmenopausal conditions, focusing on small-molecule inhibitors of the protein sclerostin. pdf Copy Link Share on Share on Share on Share on Alert
	12 Aug 2024	Zydus Lifesciences	Prabhudas Lilladhar Target	1035.80	1305.00	1250.40 (-17.16%)		Accumulate	pdf post cache		Broker Report ZYDUS LIFESCIENCES L Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	29 May 2024	Zydus Lifesciences	Geojit BNP Paribas Reco Target	1035.80	1196.00	1044.75 (-0.86%)	Target met	Accumulate	pdf post cache		Broker Report ZYDUS LIFESCIENCES LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	20 Mar 2024	Zydus Lifesciences	Sharekhan Target	1035.80	1100.00	971.40 (6.63%)	Target met	Buy	pdf post cache		Broker Report Zydus Life Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	11 Feb 2024	Zydus Lifesciences	Prabhudas Lilladhar Target	1035.80	855.00	805.05 (28.66%)	Target met	Accumulate	pdf post cache		Broker Report ZYDUS LIFESCIENCES L Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	09 Jan 2024	Zydus Lifesciences	Motilal Oswal Target	1035.80	710.00	713.00 (45.27%)	Target met	Neutral	pdf post cache		Broker Report Efforts underway to improve growth prospects for key markets Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2023	Zydus Lifesciences	Motilal Oswal Target	1035.80	660.00	597.30 (73.41%)	Target met	Neutral	pdf post cache		Broker Report Efforts underway to improve outlook in key markets Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	22 Aug 2023	Zydus Lifesciences	Geojit BNP Paribas Reco Target	1035.80	750.00	650.90 (59.13%)	Target met	Buy	pdf post cache		Broker Report ZYDUS LIFESCIENCES LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	13 Aug 2023	Zydus Lifesciences	ICICI Securities Limited Reco Target	1035.80	720.00	650.95 (59.12%)	Target met	Accumulate	pdf post cache		Broker Report US biz on a roll ICICI Securities Limited Zydus’s Q1FY24 performance was boosted by solid traction in the US (up 8.4% QoQ). US benefitted from the ongoing shortages and better sales of gRevlimid while it has started facing competition in gTrokendi XR. India branded biz grew 10% ahead of the market growth of 9%. pdf Copy Link Share on Share on Share on Share on Alert
	12 Aug 2023	Zydus Lifesciences	Prabhudas Lilladhar Target	1035.80	650.00	650.95 (59.12%)	Target met	Accumulate	pdf post cache		Broker Report ZYDUS LIFESCIENCES L Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	11 Aug 2023	Zydus Lifesciences	Motilal Oswal Target	1035.80	610.00	650.95 (59.12%)	Target met	Neutral	pdf post cache		Broker Report US quarterly revenue at historical high Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	28 Jun 2023	Zydus Lifesciences	Sharekhan Target	1035.80	663.00	582.45 (77.84%)	Target met	Buy	pdf post cache		Broker Report Zydus Life Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	19 May 2023	Zydus Lifesciences	ICICI Securities Limited Reco Target	1035.80	590.00	494.70 (109.38%)	Target met	Buy	pdf post cache		Broker Report US trajectory on a strong footing ICICI Securities Limited Zydus Lifesciences’ (Zydus) Q4FY23 performance was driven by traction in its existing products and exclusive launches such as gRevlimid and gTrokendi XR. Revenue growth and margins of the base business were also quite healthy in our opinion. pdf Copy Link Share on Share on Share on Share on Alert
	19 May 2023	Zydus Lifesciences	ICICI Direct Reco Target	1035.80	600.00	494.70 (109.38%)	Target met	Buy	pdf post cache		Broker Report Zydus Life Sciences ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	18 May 2023	Zydus Lifesciences	Prabhudas Lilladhar Target	1035.80	520.00	508.05 (103.88%)	Target met	Accumulate	pdf post cache		Broker Report ZYDUS LIFESCIENCES L Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	18 May 2023	Zydus Lifesciences	Motilal Oswal Target	1035.80	550.00	508.05 (103.88%)	Target met	Neutral	pdf post cache		Broker Report LimeRoad integration continues to hurt profitability Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners